Legal & General Group PLC Ligand Pharmaceuticals Inc Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Legal & General Group PLC holds 57,624 shares of LGND stock, worth $6.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
57,624
Previous 57,624 -0.0%
Holding current value
$6.43 Million
Previous $5.77 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$82.7 - $110.11 $766,463 - $1.02 Million
9,268 Added 19.17%
57,624 $5.77 Million
Q2 2024

Aug 14, 2024
BUY
$68.53 - $87.91 $50,301 - $64,525
734 Added 1.54%
48,356 $4.07 Million
Q1 2024

May 14, 2024
BUY
$68.64 - $89.2 $10,158 - $13,201
148 Added 0.31%
47,622 $3.48 Million
Q4 2023

Feb 15, 2024
BUY
$49.57 - $72.63 $92,646 - $135,745
1,869 Added 4.1%
47,474 $3.39 Million
Q3 2023

Nov 14, 2023
SELL
$58.86 - $72.67 $97,236 - $120,050
-1,652 Reduced 3.5%
45,605 $2.73 Million
Q2 2023

Aug 14, 2023
BUY
$69.53 - $79.33 $53,885 - $61,480
775 Added 1.67%
47,257 $3.41 Million
Q1 2023

May 15, 2023
SELL
$65.67 - $77.08 $16,417 - $19,270
-250 Reduced 0.53%
46,482 $3.42 Million
Q4 2022

Feb 14, 2023
BUY
$61.72 - $96.74 $64,497 - $101,093
1,045 Added 2.29%
46,732 $3.12 Million
Q3 2022

Nov 14, 2022
SELL
$0.01 - $107.56 $28 - $302,028
-2,808 Reduced 5.79%
45,687 $3.93 Million
Q2 2022

Aug 22, 2022
BUY
$74.52 - $117.06 $143,823 - $225,925
1,930 Added 4.14%
48,495 $4.33 Million
Q1 2022

May 16, 2022
SELL
$94.99 - $151.56 $41,035 - $65,473
-432 Reduced 0.92%
46,565 $5.24 Million
Q4 2021

Feb 14, 2022
BUY
$127.69 - $165.85 $185,150 - $240,482
1,450 Added 3.18%
46,997 $7.26 Million
Q3 2021

Nov 15, 2021
BUY
$102.33 - $144.73 $1.93 Million - $2.72 Million
18,815 Added 70.38%
45,547 $6.35 Million
Q2 2021

Aug 12, 2021
SELL
$113.03 - $155.64 $485,463 - $668,473
-4,295 Reduced 13.84%
26,732 $3.51 Million
Q1 2021

May 17, 2021
BUY
$99.52 - $215.83 $823,428 - $1.79 Million
8,274 Added 36.36%
31,027 $4.73 Million
Q4 2020

Feb 12, 2021
SELL
$80.55 - $106.05 $8,941 - $11,771
-111 Reduced 0.49%
22,753 $2.26 Million
Q3 2020

Nov 13, 2020
BUY
$89.56 - $126.72 $43,615 - $61,712
487 Added 2.18%
22,864 $2.18 Million
Q2 2020

Aug 14, 2020
BUY
$68.28 - $123.65 $87,534 - $158,519
1,282 Added 6.08%
22,377 $2.5 Million
Q1 2020

May 14, 2020
SELL
$63.37 - $107.88 $227,815 - $387,828
-3,595 Reduced 14.56%
21,095 $1.53 Million
Q4 2019

Feb 13, 2020
SELL
$96.94 - $113.59 $56,031 - $65,655
-578 Reduced 2.29%
24,690 $2.58 Million
Q3 2019

Nov 13, 2019
BUY
$86.25 - $120.16 $144,727 - $201,628
1,678 Added 7.11%
25,268 $2.51 Million
Q2 2019

Aug 14, 2019
SELL
$107.38 - $129.34 $48,428 - $58,332
-451 Reduced 1.88%
23,590 $2.69 Million
Q1 2019

May 15, 2019
BUY
$105.93 - $142.47 $186,966 - $251,459
1,765 Added 7.92%
24,041 $3.02 Million
Q4 2018

Feb 15, 2019
SELL
$128.36 - $272.13 $3.59 Million - $7.61 Million
-27,980 Reduced 55.67%
22,276 $3.02 Million
Q3 2018

Nov 20, 2018
BUY
$211.18 - $274.49 $772,918 - $1 Million
3,660 Added 7.85%
50,256 $13.8 Million
Q2 2018

Aug 10, 2018
BUY
$150.77 - $207.98 $243,342 - $335,679
1,614 Added 3.59%
46,596 $9.67 Million
Q1 2018

May 17, 2018
BUY
$138.63 - $182.62 $387,054 - $509,875
2,792 Added 6.62%
44,982 $7.38 Million
Q4 2017

Feb 13, 2018
BUY
$128.36 - $147.04 $5.42 Million - $6.2 Million
42,190
42,190 $5.78 Million

Others Institutions Holding LGND

# of Institutions
257
Shares Held
18.2M
Call Options Held
26.8K
Put Options Held
9.3K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email